-
CONMED board member Martha Aronson steps down
-
Conmed (CNMD) option IV near low end of range as share price down 4.1%
-
Needham Downgrades CONMED (CNMD) to Hold
-
Conmed (CNMD) Appoints LaVerne Council as Chair of the Board of Directors
-
Conmed (CNMD) Misses Q1 EPS by 21c, provides guidance
-
Stifel Downgrades CONMED (CNMD) to Hold
-
BofA Comments on Trump and Mexico Tariff Delay Impact to Medical Technology Names
-
Conmed (CNMD) Appoints Mark Kaye to its Board
-
CONMED (CNMD) PT Lowered to $91 at Needham
-
JPMorgan Downgrades CONMED (CNMD) to Neutral
-
Conmed (CNMD) Tops Q4 EPS by 13c ; Offers Guidance
-
Stifel Reiterates Buy Rating on CONMED (CNMD)
-
Conmed (CNMD) Tops Q3 EPS by 6c, Misses on Revenue; offers FY24 Guidance
-
Conmed (CNMD) Announces CEO Retirement
-
Needham Reiterates Buy Rating on CONMED (CNMD)
-
Conmed (CNMD) Announces Preliminary Third Quarter Financial Information
-
CONMED (CNMD) PT Lowered to $80 at Piper Sandler
-
CONMED (CNMD) PT Lowered to $97 at Needham
-
Conmed (CNMD) Tops Q2 EPS by 7c, provides guidance
-
CONMED (CNMD) PT Lowered to $106 at Needham

